Published in Cancer Weekly, February 12th, 2008
Chief Executive, Dr Peter Smith, said that the company was delighted with the outcome of the discussions. "Alchemia now has a very clear path to market for HA-irinotecan following on from the highly successful Phase II clinical trial completed last year. During our pre-IND meeting with the FDA, the agency agreed on the proposed pivotal trial design and we will file our IND application to begin the trial in the very near future....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.